IRLA.US IRulya Therapeutics Inc.
- Market cap
- USD 431M
- P/E
- -
- P/B
- 2.21x
- ROE
- -
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is IRLA.US undervalued?
Graham numberThe Graham number of IRulya Therapeutics Inc. cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
IRulya Therapeutics Inc. fundamental analysis
No fundamental analysis for IRulya Therapeutics Inc. yet.
IRulya Therapeutics Inc. stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About IRulya Therapeutics Inc.
IRulya Therapeutics Inc., a biotechnology company, focuses on acquiring, developing, and commercializing therapeutics for patients with debilitating and rare diseases. The company's lead asset candidate comprises eDSP, which is in Phase 3 for the treatment of rare pediatric neurodegenerative diseases, including A-T, an inherited autosomal recessive neurodegenerative and immunodeficiency disorder caused by mutations in the ATM gene. Its AIDE technology platform is a drug/devi…
Full company profileIRulya Therapeutics Inc. financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
IRulya Therapeutics Inc. annual financial statements
| Item | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||||
| Revenue | - | - | - | - | - | 0.00 | 0.00 | 0.00 | 0.00 | - |
| Gross Profit | -45.0K | -51.0K | - | - | - | - | - | - | -142K | - |
| Operating Income | -10.4M | -12.1M | -39.2M | -78.9M | -90.3M | -52.0M | -34.6M | -57.3M | -50.4M | -139M |
| EBITDA | -10.3M | -12.1M | -39.0M | -78.6M | -89.6M | -51.0M | -26.8M | -36.0M | -80.6M | -77.2M |
| Net Income | -12.2M | -12.5M | -37.0M | -76.8M | -89.9M | -51.7M | -31.4M | -56.8M | -84.0M | -89.8M |
| EPS | -114 | -116 | -389 | -527 | -605 | -308 | -169 | -263 | -335 | -7.48 |
| Balance Sheet | ||||||||||
| Total Assets | 7.72M | 72.9M | 124M | 189M | 133M | 104M | 180M | 114M | 93.5M | 106M |
| Total Liabilities | 28.0M | 1.46M | 8.89M | 17.2M | 14.6M | 3.32M | 95.1M | 84.3M | 129M | 28.4M |
| Shareholders' Equity | -20.3M | 71.4M | 115M | 172M | 119M | 101M | 85.1M | 30.1M | -35.7M | -65.7M |
| Cash & Short-term Investments | 7.34M | 71.7M | 99.9M | 134M | 107M | 90.2M | 75.1M | 40.8M | 17.8M | 105M |
| Total Debt | 7.17M | - | - | 446K | 1.16M | 453K | 13.8M | 14.8M | 18.5M | - |
| Cash Flow | ||||||||||
| Operating Cash Flow | -9.83M | -11.7M | -33.3M | -50.8M | -62.9M | -44.0M | -18.3M | -31.9M | -41.4M | -48.5M |
| Capital Expenditure | 77.0K | 212K | 55.0K | 52.0K | 180K | 133K | 160K | 257K | 352K | 100K |
| Free Cash Flow | -9.90M | -11.9M | -33.3M | -50.9M | -63.1M | -44.2M | -18.5M | -32.2M | -41.8M | -48.6M |
| Ratios | ||||||||||
| ROE | - | -17.5% | -32.0% | -44.6% | -75.8% | -51.4% | -36.9% | -188.5% | - | - |
| ROA | -158.5% | -17.1% | -29.7% | -40.6% | -67.5% | -49.7% | -17.4% | -49.6% | -89.8% | -84.3% |
| Debt to Equity | - | - | - | 0.00x | 0.01x | 0.00x | 0.16x | 0.49x | - | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Debt to Equity
- Total debt divided by shareholders' equity.
IRulya Therapeutics Inc. dividends
IRulya Therapeutics Inc. has not paid dividends in the last 9 fiscal years.
Last stock split: 1:20 on Jun 30, 2026.
Who owns IRulya Therapeutics Inc.
- Insiders 1.01%
- Institutions 12.11%
- Public & others 86.88%
- Shares outstanding 10.8M
- Free float 680K
Top funds holding IRLA.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Fidelity Extended Market Index | 5.34K | 0.05% | -0.37% | Sep 2026 |
| Fidelity Series Total Market Index | 1.25K | 0.01% | 0.00% | Sep 2026 |
| Fidelity Total Market Index | 1.15K | 0.01% | 0.00% | Sep 2026 |
| Fidelity Nasdaq Composite Index | 580.00 | 0.01% | 0.00% | Aug 2026 |
| Guggenheim Active Allocation Fund | 2.00 | 0.00% | +100.00% | Aug 2026 |
Top institutions holding IRLA.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Ikarian Capital, LLC | 72.3K | 0.36% | 0.00% | Jun 2026 |
| Millennium Management LLC | 70.8K | 0.35% | +465.37% | Jun 2026 |
| Balyasny Asset Management LLC | 70.0K | 0.34% | 0.00% | Jun 2026 |
| Squadron Capital Management LLC | 40.4K | 0.20% | 0.00% | Jun 2026 |
| Shay Capital LLC | 17.5K | 0.09% | +97.04% | Jun 2026 |
| BOOTHBAY FUND MANAGEMENT, LLC | 13.9K | 0.07% | 0.00% | Jun 2026 |
| Jane Street Group LLC | 12.6K | 0.06% | 0.00% | Jun 2026 |
| Vanguard Capital Management, LLC | 12.0K | 0.06% | +422.06% | Jun 2026 |
| Cormorant Asset Management, LLC | 5.50K | 0.03% | 0.00% | Jun 2026 |
| UBS Group AG | 4.73K | 0.02% | +157,566.67% | Jun 2026 |
| Morgan Stanley - Brokerage Accounts | 4.08K | 0.02% | +102,000.00% | Jun 2026 |
| Vanguard Fiduciary Trust Co | 3.61K | 0.02% | +211.02% | Jun 2026 |
| BlackRock Inc | 1.70K | 0.01% | -28.06% | Jun 2026 |
| Tower Research Capital LLC | 567.00 | 0.00% | +1,188.64% | Jun 2026 |
| Operose Advisors LLC | 159.00 | 0.00% | 0.00% | Jun 2026 |
| Fortitude Family Office LLC | 40.00 | 0.00% | 0.00% | Jun 2026 |
| Barclays PLC | 27.00 | 0.00% | 0.00% | Jun 2026 |
| Integrated Wealth Concepts LLC | 12.00 | 0.00% | 0.00% | Jun 2026 |
| Wells Fargo & Co | 10.00 | 0.00% | 0.00% | Jun 2026 |
| Hanson Mcclain Inc | 8.00 | 0.00% | 0.00% | Jun 2026 |
IRulya Therapeutics Inc. company profile
- Company name
- IRulya Therapeutics Inc.
- Ticker
- IRLA.US
- Exchange
- USA Stocks
- Listed since
- May 9, 2019
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 38
- Fiscal year end
- December
- Address
- 101 College Street, New Haven, CT, United States, 06510
- Phone
- 415 910 5717
- Website
- irulya.com
About IRulya Therapeutics Inc.
IRulya Therapeutics Inc., a biotechnology company, focuses on acquiring, developing, and commercializing therapeutics for patients with debilitating and rare diseases. The company's lead asset candidate comprises eDSP, which is in Phase 3 for the treatment of rare pediatric neurodegenerative diseases, including A-T, an inherited autosomal recessive neurodegenerative and immunodeficiency disorder caused by mutations in the ATM gene. Its AIDE technology platform is a drug/device combination platform that uses an automated process to encapsulate a drug into a patient's own red blood cells and consists of automated equipment, the RCL, a sterile single-use consumable treatment kit comprising medical device kits, syringe kits, and process solutions. IRulya Therapeutics Inc. was formerly known as Quince Therapeutics, Inc. and changed its name to IRulya Therapeutics Inc. in October 2026. The company was incorporated in 2012 and is headquartered in New Haven, Connecticut.
IRulya Therapeutics Inc. management
4- Dr. Brigette Roberts M.D.CEO, Principal Executive Officer & Director · born 1975
- Mr. John C. Militello CPACFO, Principal Financial Officer & Principal Accounting Officer · born 1973
- Dr. Keith R. Fandrick Ph.D.Chief Operating Officer · born 1979
- Dr. Guenter R. Janhofer M.D., Ph.D.Chief Scientific Officer